The combination of Kras mutations and injury-induced inflammation is associated with a variety of gene expression programs, some of which are maintained in PDAC, suggesting that the combined effect of early genetic mutations and tissue injury primes cells for tumour development (Alonso-Curbelo et al., 2021; Burdziak et al., 2023). The gene discussed is KRAS; the disease is neoplasm.